The University of Chicago Header Logo

Connection

Kerstin Stenson to Humans

Back to Details
This is a "connection" page, showing publications Kerstin Stenson has written about Humans.
Kerstin Stenson
Connection Strength
0.485
Humans
  1. Enhanced recovery after surgery in head and neck surgery: Reduced opioid use and length of stay. Laryngoscope. 2020 05; 130(5):1227-1232.
    View in: PubMed
    Score: 0.022
  2. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7.
    View in: PubMed
    Score: 0.013
  3. Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9.
    View in: PubMed
    Score: 0.012
  4. Occurrence and multiple recurrence of severe vasospasm of the upper extremity following thorascopic sympathectomy for hyperhidrosis. Eur J Vasc Endovasc Surg. 2011 Feb; 41(2):264-6.
    View in: PubMed
    Score: 0.012
  5. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
    View in: PubMed
    Score: 0.011
  6. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Nov; 135(11):1133-6.
    View in: PubMed
    Score: 0.011
  7. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009 Sep; 135(9):876-80.
    View in: PubMed
    Score: 0.011
  8. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.011
  9. Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95.
    View in: PubMed
    Score: 0.010
  10. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
    View in: PubMed
    Score: 0.009
  11. Air pollution is associated with increased incidence-rate of head and neck cancers: A nationally representative ecological study. Oral Oncol. 2024 Mar; 150:106691.
    View in: PubMed
    Score: 0.008
  12. Therapeutic options for laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2087-9.
    View in: PubMed
    Score: 0.008
  13. A Nationwide Analysis of Head and Neck Fibromatoses. Laryngoscope. 2024 May; 134(5):2228-2235.
    View in: PubMed
    Score: 0.007
  14. A nationwide analysis of salvage surgery for laryngeal cancer in the elderly. Head Neck. 2023 11; 45(11):2915-2924.
    View in: PubMed
    Score: 0.007
  15. Association of HPV status with survival after surgical salvage of oropharyngeal cancers. Am J Otolaryngol. 2022 Jul-Aug; 43(4):103491.
    View in: PubMed
    Score: 0.007
  16. Presence of CrkI-containing microvesicles in squamous cell carcinomas could have ramifications on tumor biology and cancer therapeutics. Sci Rep. 2022 03 21; 12(1):4803.
    View in: PubMed
    Score: 0.007
  17. Laparoscopic Transhiatal Esophagectomy With En Bloc Posterior Tracheal Wall Resection. Ann Thorac Surg. 2022 12; 114(6):e409-e411.
    View in: PubMed
    Score: 0.007
  18. The prevalence of violence investigated in a pregnant population in Sweden. J Psychosom Obstet Gynaecol. 2001 Dec; 22(4):189-97.
    View in: PubMed
    Score: 0.007
  19. Effect of histopathological grade on treatment and survival in base of tongue adenocarcinoma. Am J Otolaryngol. 2022 May-Jun; 43(3):103265.
    View in: PubMed
    Score: 0.006
  20. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
    View in: PubMed
    Score: 0.006
  21. Laryngeal Chondrosarcoma Characteristics and Survival Analysis in the National Cancer Database. Otolaryngol Head Neck Surg. 2022 01; 166(1):101-108.
    View in: PubMed
    Score: 0.006
  22. Clinical Practice Guideline: Opioid Prescribing for Analgesia After Common Otolaryngology Operations. Otolaryngol Head Neck Surg. 2021 04; 164(2_suppl):S1-S42.
    View in: PubMed
    Score: 0.006
  23. Clinical Practice Guideline: Opioid Prescribing for Analgesia After Common Otolaryngology Operations Executive Summary. Otolaryngol Head Neck Surg. 2021 04; 164(4):687-703.
    View in: PubMed
    Score: 0.006
  24. Women's attitudes to being asked about exposure to violence. Midwifery. 2001 Mar; 17(1):2-10.
    View in: PubMed
    Score: 0.006
  25. Cytopathologic assessment of gloves and instruments after major head and neck surgery. Am J Otolaryngol. 2021 May-Jun; 42(3):102876.
    View in: PubMed
    Score: 0.006
  26. Functional outcomes after extracapsular dissection with partial facial nerve dissection for small and large parotid neoplasms. Am J Otolaryngol. 2021 Jan - Feb; 42(1):102770.
    View in: PubMed
    Score: 0.006
  27. Willingness of patients to attend abdominal aortic aneurysm surveillance: The implications of COVID-19 on restarting the National Abdominal Aortic Aneurysm Screening Programme. Br J Surg. 2020 12; 107(13):e646-e647.
    View in: PubMed
    Score: 0.006
  28. Occult Lymph Node Metastasis in Early-Stage Glottic Cancer in the National Cancer Database. Laryngoscope. 2021 04; 131(4):E1139-E1146.
    View in: PubMed
    Score: 0.006
  29. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
    View in: PubMed
    Score: 0.006
  30. Enhanced recovery protocol for transoral robotic surgery demonstrates improved analgesia and narcotic use reduction. Am J Otolaryngol. 2020 Nov - Dec; 41(6):102649.
    View in: PubMed
    Score: 0.006
  31. Implementation of Preoperative Screening Protocols in Otolaryngology During the COVID-19 Pandemic. Otolaryngol Head Neck Surg. 2020 08; 163(2):265-270.
    View in: PubMed
    Score: 0.006
  32. Management of the Clinical and Academic Mission in an Urban Otolaryngology Department During the COVID-19 Global Crisis. Otolaryngol Head Neck Surg. 2020 07; 163(1):162-169.
    View in: PubMed
    Score: 0.006
  33. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
    View in: PubMed
    Score: 0.006
  34. Prognostic Indicators in Base of Tongue Adenocarcinoma: A Population-Based Analysis. Ear Nose Throat J. 2021 Sep; 100(5_suppl):467S-471S.
    View in: PubMed
    Score: 0.006
  35. Association of Perioperative Opioid-Sparing Multimodal Analgesia With Narcotic Use and Pain Control After Head and Neck Free Flap Reconstruction. JAMA Facial Plast Surg. 2019 Sep 01; 21(5):446-451.
    View in: PubMed
    Score: 0.006
  36. Heterogeneity in the clinical presentation, diagnosis, and treatment initiation of p16-positive oropharyngeal cancer. Am J Otolaryngol. 2019 Sep - Oct; 40(5):626-630.
    View in: PubMed
    Score: 0.005
  37. Clinical features and outcomes in young adults with oral tongue cancer. Am J Otolaryngol. 2019 Jan - Feb; 40(1):93-96.
    View in: PubMed
    Score: 0.005
  38. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
    View in: PubMed
    Score: 0.005
  39. Superselective retrograde lymphatic duct embolization for management of postoperative lymphatic leak. Diagn Interv Radiol. 2017 Sep-Oct; 23(5):379-380.
    View in: PubMed
    Score: 0.005
  40. Extranodal non-Hodgkin's lymphoma of the head and neck: presentation in the facial bones. Am J Otolaryngol. 1996 Jul-Aug; 17(4):276-80.
    View in: PubMed
    Score: 0.004
  41. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.004
  42. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
    View in: PubMed
    Score: 0.004
  43. Hemangiopericytoma of the oral cavity. Otolaryngol Head Neck Surg. 1996 Feb; 114(2):339-40.
    View in: PubMed
    Score: 0.004
  44. Locoregional Recurrent or Second Primary Head and Neck Cancer: Management Strategies and Challenges. Am Soc Clin Oncol Educ Book. 2016; 35:e284-92.
    View in: PubMed
    Score: 0.004
  45. Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):512-22.
    View in: PubMed
    Score: 0.004
  46. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.004
  47. Pathologic quiz case 2. Burn scar carcinoma (BSC). Arch Otolaryngol Head Neck Surg. 1994 Sep; 120(9):1016-7, 1020-1.
    View in: PubMed
    Score: 0.004
  48. Discrepant serum and urine ß-hCG results due to production of ß-hCG by a cribriform-morular variant of thyroid papillary carcinoma. Clin Chim Acta. 2015 Jan 01; 438:181-5.
    View in: PubMed
    Score: 0.004
  49. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.004
  50. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
    View in: PubMed
    Score: 0.004
  51. Ingestion of caustic cosmetic products. Otolaryngol Head Neck Surg. 1993 Nov; 109(5):821-5.
    View in: PubMed
    Score: 0.004
  52. Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72.
    View in: PubMed
    Score: 0.004
  53. Experience with one-stage laryngotracheal reconstruction. Int J Pediatr Otorhinolaryngol. 1993 May; 27(1):55-64.
    View in: PubMed
    Score: 0.004
  54. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.003
  55. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
    View in: PubMed
    Score: 0.003
  56. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
    View in: PubMed
    Score: 0.003
  57. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92.
    View in: PubMed
    Score: 0.003
  58. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.003
  59. Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61.
    View in: PubMed
    Score: 0.003
  60. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
    View in: PubMed
    Score: 0.003
  61. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
    View in: PubMed
    Score: 0.003
  62. Cystic hygroma of the parotid gland. Ann Otol Rhinol Laryngol. 1991 Jun; 100(6):518-20.
    View in: PubMed
    Score: 0.003
  63. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
    View in: PubMed
    Score: 0.003
  64. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
    View in: PubMed
    Score: 0.003
  65. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34.
    View in: PubMed
    Score: 0.003
  66. Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck. 2010 Nov; 32(11):1519-27.
    View in: PubMed
    Score: 0.003
  67. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
    View in: PubMed
    Score: 0.003
  68. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.003
  69. Retrograde endoscopic-assisted esophageal dilation. J Gastrointest Surg. 2010 Jul; 14(7):1186-9.
    View in: PubMed
    Score: 0.003
  70. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11.
    View in: PubMed
    Score: 0.003
  71. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.003
  72. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
    View in: PubMed
    Score: 0.003
  73. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
    View in: PubMed
    Score: 0.003
  74. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
    View in: PubMed
    Score: 0.003
  75. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
    View in: PubMed
    Score: 0.003
  76. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.003
  77. The thoracoacromial trunk: alternative recipient vessels in reoperative head and neck reconstructive microsurgery. Plast Reconstr Surg. 2008 Jan; 121(1):88-94.
    View in: PubMed
    Score: 0.002
  78. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
    View in: PubMed
    Score: 0.002
  79. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
    View in: PubMed
    Score: 0.002
  80. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.002
  81. A simplified design of a dual island fasciocutaneous free flap for simultaneous pharyngoesophageal and anterior neck reconstruction. J Reconstr Microsurg. 2006 Feb; 22(2):105-12.
    View in: PubMed
    Score: 0.002
  82. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
    View in: PubMed
    Score: 0.002
  83. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
    View in: PubMed
    Score: 0.002
  84. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86.
    View in: PubMed
    Score: 0.002
  85. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
    View in: PubMed
    Score: 0.002
  86. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
    View in: PubMed
    Score: 0.002
  87. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
    View in: PubMed
    Score: 0.002
  88. Malignant carotid body tumor. Head Neck. 2004 Mar; 26(3):301-6.
    View in: PubMed
    Score: 0.002
  89. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.002
  90. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
    View in: PubMed
    Score: 0.002
  91. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003 Aug; 14(8):1306-11.
    View in: PubMed
    Score: 0.002
  92. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7.
    View in: PubMed
    Score: 0.002
  93. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.002
  94. Radiology quiz case 2. Verrucous carcinoma of the maxillary antrum. Arch Otolaryngol Head Neck Surg. 2003 Feb; 129(2):259, 260-1.
    View in: PubMed
    Score: 0.002
  95. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.002
  96. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.002
  97. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
    View in: PubMed
    Score: 0.002
  98. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun; 11(6):721-8.
    View in: PubMed
    Score: 0.001
  99. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.001
  100. Patients' priorities among treatment effects in head and neck cancer: evaluation of a new assessment tool. Head Neck. 1999 Sep; 21(6):538-46.
    View in: PubMed
    Score: 0.001
  101. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999 Mar; 17(3):1020-8.
    View in: PubMed
    Score: 0.001
  102. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
    View in: PubMed
    Score: 0.001
  103. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
    View in: PubMed
    Score: 0.001
  104. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.001
  105. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
    View in: PubMed
    Score: 0.001
  106. Pathologic quiz case 2. Teflon granuloma. Arch Otolaryngol Head Neck Surg. 1997 Feb; 123(2):231, 233.
    View in: PubMed
    Score: 0.001
  107. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.